Prognostic value of lipoprotein (a) with low cholesterol unclear

Prognostic value of lipoprotein (a) with low cholesterol unclear

(HealthDay)—Lipoprotein (a) (Lp[a]) has utility in assessing cardiovascular risk in patients with coronary artery disease (CAD); however, the prognostic value of Lp(a) in patients with low cholesterol levels remains unclear, according to a study published online Oct. 23 in the Journal of the American College of Cardiology.

Michelle O'Donoghue, M.D., from Brigham and Women's Hospital in Boston, and colleagues combined data from three studies of patients with CAD (6,762 participants) and eight previously published studies in which plasma Lp(a) was measured (for a total of 18,979 patients).

The researchers found that increasing levels of Lp(a) were not associated with risk when modeled as a continuous variable (OR, 1.03) or by quintile (OR Q5:Q1, 1.05), based on data from the three studies. Utilizing the total combined data, subjects with Lp(a) levels in the highest quintile were at increased risk of cardiovascular events (OR, 1.40); however, there was significant between-study heterogeneity (P = 0.001). The association between Lp(a) and cardiovascular events, when stratified on the basis of low-density lipoprotein (LDL) cholesterol, was significant in studies in which average LDL cholesterol was ≥130 mg/dL (OR, 1.46; P < 0.001), whereas this relationship was not significant for studies with an average LDL cholesterol <130 mg/dL (OR, 1.20; P = 0.21).

"Lp(a) is significantly associated with the risk of cardiovascular events in patients with established CAD; however, there exists marked heterogeneity across trials," O'Donoghue and colleagues conclude. "In particular, the of Lp(a) in patients with low remains unclear."

Several authors disclosed financial ties to the pharmaceutical industry, including companies that funded some studies included in the meta-analysis.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Statins reduce CV events in CAD patients with very low LDL-C

Sep 01, 2013

Aggressive treatment with statins reduces the risk of subsequent cardiovascular events in patients with coronary artery disease even if they have very low LDL cholesterol levels, reveals research presented at ESC Congress ...

Cinnamon cuts blood glucose levels in diabetes patients

Sep 16, 2013

(HealthDay)—Consumption of cinnamon is associated with favorable reductions in plasma glucose and lipid levels, according to research published in the September/October issue of the Annals of Family Me ...

Recommended for you

Real-time volume imaging of hearts

6 hours ago

A new ultrasound system from Siemens enables doctors to carry out heart examinations through the esophagus for the first time. The system supplies 3D images of the heart as well as additional real-time information ...

Post-PCI bleeding rates vary widely across hospitals

Nov 27, 2014

(HealthDay)—Patient case-mix and procedural factors may contribute to wide variation in the hospital rates of bleeding after percutaneous coronary intervention (PCI), according to research published online ...

Most seniors eligible for statin Rx under new guidelines

Nov 25, 2014

(HealthDay)—Most older Americans qualify for treatment with statins under new guidelines for the treatment of blood cholesterol released late last year by the American College of Cardiology and the American ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

cardiacguy
not rated yet Nov 22, 2013
Lpa is proinflammary to the coronary artery endothelium. In a low LDL environment, the subsequent formation of large lipid rich plaques is suppressed reducing the risk of acute MI. If LDL is elevated Lpa adds to acute MI risk.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.